Bolt Biotherapeutics   Report issue

For profit Phase 1
Founded: Redwood City CA United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04278144
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bolt Biotherapeutics | Bolt Biotherapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

bdc-1001 (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2